Financials data is unavailable for this security.
View more
Year on year Lumos Pharma Inc had net income fall 9.57% from a loss of 31.06m to a larger loss of 34.03m despite a 34.67% increase in revenues from 1.52m to 2.05m.
| Gross margin | -- |
|---|---|
| Net profit margin | -2,405.72% |
| Operating margin | -2,531.70% |
| Return on assets | -91.98% |
|---|---|
| Return on equity | -132.56% |
| Return on investment | -107.92% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Lumos Pharma Inc fell by 20.93m. However, Cash Flow from Investing totalled 10.74m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 31.10m for operations while cash used for financing totalled 576.00k.
| Cash flow per share | -4.42 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.26 |
|---|---|
| Tangible book value per share | 1.26 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.23 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
